Related Experiment Video
Updated: May 17, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Low frequency of filaggrin null mutations in Croatia and their relation with allergic diseases
I Sabolić Pipinić1, V M Varnai, R Turk
1Occupational Health and Environmental Medicine Unit, Institute for Medical Research and Occupational Health, Zagreb, Croatia. ivanasp@imi.hr
Abstract:
Filaggrin gene (FLG) null mutations are considered associated with atopic dermatitis. This study was conducted to determine the prevalence of FLG null mutations R501X, 2282del4, R2447X and S3247X in the Croatian population and their role in the occurrence of allergic diseases including atopic dermatitis, allergic rhinitis, asthma and allergic contact dermatitis (ACD). Study enrolled 440 freshmen with defined allergic diseases by means of both present symptoms in International Study of Asthma and Allergies in Childhood questionnaire (relevant respiratory and/or skin symptoms) and markers of allergic sensitization (positive skin prick and/or patch test). FLG null mutations were successfully genotyped in 423 students of which 11 (2.6%) were carriers of FLG null mutation: 1/423 (0.2%) was heterozygous for R501X and 10/423 (2.4%) were heterozygous for 2282del4. No carriers of R2447X and S3247X mutations were identified. In wild-type FLG carriers (412 subjects), atopic dermatitis was present in 45 (11%), allergic rhinitis in 70 (17%) and allergic asthma in 29 (7%) students. Twenty-five of 393 (7%) patch-tested wild-type FLG carriers had ACD. Among 11 FLG null mutation carriers, four had one or more allergic diseases, and five had reported skin symptoms without defined allergic sensitization (positive skin prick test and/or patch test). FLG null mutations were not confirmed as a predictor of analysed allergic diseases, but were confirmed as an independent predictor of skin symptoms (OR 17.19, 95% CI 3.41-86.6, P < 0.001). Our results in general indicate a low frequency of FLG null mutations in the studied Croatian population supporting a theory of a latitude-dependent distribution of FGL null mutations in Europe, with a decreasing north-south gradient of R501X and 2282del4 mutation frequency. The relation between FLG null mutations and skin disorders was confirmed.
Insights
Filaggrin gene (FLG) null mutations are uncommon in Croatia and do not predict common allergic diseases. However, FLG mutations are linked to skin symptoms, suggesting a latitude-dependent distribution in Europe.
Area of Science:
- Genetics
- Dermatology
- Allergology
Background:
- Filaggrin gene (FLG) null mutations are associated with atopic dermatitis.
- Understanding the prevalence and impact of FLG mutations in diverse populations is crucial.
Purpose of the Study:
- To determine the prevalence of specific FLG null mutations (R501X, 2282del4, R2447X, S3247X) in the Croatian population.
- To investigate the role of these mutations in allergic diseases: atopic dermatitis, allergic rhinitis, asthma, and allergic contact dermatitis (ACD).
Main Methods:
- Genotyping of FLG null mutations in 423 Croatian freshmen with diagnosed allergic diseases.
- Analysis of allergic disease prevalence (symptoms and sensitization markers) in mutation carriers versus wild-type FLG subjects.
Main Results:
- FLG null mutations were found in 2.6% of subjects (11/423), with R501X (0.2%) and 2282del4 (2.4%) being the only identified mutations.
- No significant association was found between FLG null mutations and the occurrence of atopic dermatitis, allergic rhinitis, or asthma.
- FLG null mutations were confirmed as an independent predictor of skin symptoms (OR 17.19, P < 0.001), independent of allergic sensitization.
Conclusions:
- The frequency of FLG null mutations in Croatia is low, supporting a north-south gradient in Europe.
- FLG null mutations are not predictive of major allergic diseases but are strongly associated with skin symptoms.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Types of Intermediate Filaments
Cytoskeletal Linker Proteins - Plakins
Pharmacogenomics: Identification of New Drug Targets
